Lumida
/KRYS
⌘K
Krystal Biotech Inc

Krystal Biotech Inc

KRYS
$347.00USD+0.42%+1.45 today

MARKET CAP

10.3B

P/E (TTM)

46.4x

FWD P/E

DAY RANGE

$347 – $354

52W RANGE

$137
$383

AI Summary

Stalk
StalkMedium

KRYS remains in a Stage 2 advancing structure with clear higher highs and higher lows confirming medium-term bullishness, but recent weakness has led to a healthy pullback into the 9EMA, 20EMA, and 50SMA support zone. Short-term timing is neutral as the pullback lacks visible acceptance, so execution is deferred until absorption and a clean bounce off key EMAs before initiating exposure.

  • Q1 net revenue $116.4M (+32% YoY; +9% sequential growth).
  • Gross margin 95% reflects efficient manufacturing processes.
  • Negative earnings yield suggests potential overvaluation risk.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2023FY 2024FY 2025TREND
Sales, Adj.$50.7M$290.5M$389.1M
YoY %+473.0%+33.9%
P / Sales68.4x16.0x19.0x
EV / Sales62.1x15.2x18.0x
Gross Profit, Adj.$47.6M$270.5M$366.1M
YoY %+468.1%+35.4%
Margin %93.9%93.1%94.1%
EV / Gross Profit66.2x16.4x19.1x
EBITDA, Adj.$-92.1M$109.2M$167.0M
YoY %+21.6%+218.6%+52.9%
Margin %-181.7%37.6%42.9%
EV / EBITDA-34.2x40.5x41.9x
EBIT$-109.6M$65.7M$161.3M
YoY %+24.5%+160.0%+145.3%
Margin %-216.2%22.6%41.5%
EV / EBIT-28.7x67.3x43.4x
Net Income$10.9M$89.2M$204.8M
YoY %+107.8%+715.6%+129.7%
Net Margin21.6%30.7%52.6%
EPS (GAAP)$0.39$3.00$6.84
YoY %+107.1%+669.2%+128.0%